KROMATID, a leader in next-generation genomic structural analysis, announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million, with the round led by BroadOak Capital Partners and participation from both existing and new strategic investors.
The Boulder, Colorado-based company specializes in delivering genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with high clarity and resolution through proprietary imaging and bioinformatics capabilities.
Strategic Investment to Scale Operations
The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy.
"We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients."
Addressing Critical Industry Need
Bill Snider, Partner at BroadOak Capital Partners, highlighted the company's differentiated position in the market. "KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry," Snider said. "We are proud to continue our partnership as they enter their next phase of growth."
Growth and Expansion Plans
Over the next 12-18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis.
The company's platform supports therapeutic innovation from discovery through regulatory approval by combining proprietary imaging and bioinformatics capabilities to detect chromosomal structural rearrangements with unmatched clarity and resolution.
